Comparison of the pharmacological activity of idarubicin and doxorubicin for retinoblastoma

Pediatr Blood Cancer. 2019 Jan;66(1):e27441. doi: 10.1002/pbc.27441. Epub 2018 Sep 5.

Authors

Santiago Zugbi¹, Ursula Winter^{1

2}, Agustina Castañon¹, Claudia Sampor^{2

3}, Guillermo Chantada^{2

4}, Paula Schaiquevich^{1

2}

Affiliations

¹ Unit of Clinical Pharmacokinetics, Hospital de Pediatría Prof. Dr. JP Garrahan, Buenos Aires, Argentina.
² National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
³ Department of Hematology-Oncology, Hospital de Pediatría Prof. Dr. JP Garrahan, Buenos Aires, Argentina.
⁴ Precision Medicine Department, Hospital de Pediatría Prof. Dr. JP Garrahan, Buenos Aires, Argentina.

PMID: 30183141
DOI: 10.1002/pbc.27441

No abstract available

Publication types

Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibiotics, Antineoplastic / pharmacology*
Apoptosis / drug effects*
Cell Proliferation / drug effects
Doxorubicin / pharmacology*
Humans
Idarubicin / pharmacology*
Retinal Neoplasms / drug therapy
Retinal Neoplasms / pathology*
Retinoblastoma / drug therapy
Retinoblastoma / pathology*
Tumor Cells, Cultured

Substances

Antibiotics, Antineoplastic
Doxorubicin
Idarubicin